Literature DB >> 31476732

Long-term prognostic value of coronary flow reserve in psoriasis patients.

Stefano Piaserico1, Elena Osto2, Giulia Famoso3, Roberta Montisci4, Laura De Michieli3, Irene Zanetti3, Sabino Iliceto3, Francesco Tona5.   

Abstract

BACKGROUND AND AIMS: Psoriasis affects more than 3% of the general population and is associated with an increased risk of premature cardiovascular events and death. We assessed the prognostic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients asymptomatic for cardiovascular disease.
METHODS: We retrospectively analyzed 153 prospectively collected patients affected by psoriasis (123 male; age 36 ± 8 years) without cardiovascular disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. CFR ≤2.5 was the cut off to define the presence of coronary microvascular dysfunction (CMD).
RESULTS: CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was associated with severe psoriasis (OR 3.1, p = 0.03), psoriatic arthritis (OR 2.9, p = 0.03), hypertension (OR 4.1, p = 0.009), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, p = 0.03). Patients with CFR ≤2.5 had a lower survival free from events (p < 0.0001).
CONCLUSIONS: In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help identify patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Coronary flow reserve; Coronary microcirculation; Prognosis; Psoriasis

Year:  2019        PMID: 31476732     DOI: 10.1016/j.atherosclerosis.2019.08.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

Review 1.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 2.  Vasomotor Dysfunction in Patients with Ischemia and Non-Obstructive Coronary Artery Disease: Current Diagnostic and Therapeutic Strategies.

Authors:  Amr Abouelnour; Tommaso Gori
Journal:  Biomedicines       Date:  2021-11-26

3.  Multiparametric analysis of coronary flow in psoriasis using a coronary flow reserve companion.

Authors:  Francesco Tona; Elena Osto; Peter L M Kerkhof; Roberta Montisci; Giulia Famoso; Giulia Lorenzoni; Laura De Michieli; Annagrazia Cecere; Irene Zanetti; Giovanni Civieri; Sabino Iliceto; Stefano Piaserico
Journal:  Eur J Clin Invest       Date:  2021-11-25       Impact factor: 5.722

Review 4.  Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Authors:  J J Wu; A Kavanaugh; M G Lebwohl; R Gniadecki; J F Merola
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-14       Impact factor: 9.228

5.  Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network.

Authors:  An-Hai Li; Meng-Meng Qi; Wen-Wen Li; Xiao-Qian Yu; Li-Li Yang; Jun Wang; Ding Li
Journal:  Heliyon       Date:  2022-09-17

Review 6.  The Association Between Psoriasis and Cardiovascular Diseases.

Authors:  Ahmed Zwain; Mohanad Aldiwani; Hussein Taqi
Journal:  Eur Cardiol       Date:  2021-05-13

7.  Coronary microvascular dysfunction in patients with psoriasis.

Authors:  Brittany Weber; Lourdes M Perez-Chada; Sanjay Divakaran; Jenifer M Brown; Viviany Taqueti; Sharmila Dorbala; Ron Blankstein; Katherine Liao; Joseph F Merola; Marcelo Di Carli
Journal:  J Nucl Cardiol       Date:  2020-05-17       Impact factor: 3.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.